Search Results
Your search for ,WHo matches 20365 pages
Showing 8151 - 8200New ASCO Guideline Highlights Need to Improve Germline, Somatic Tumor Testing in Epithelial Ovarian Cancer
A new ASCO clinical practice guideline provides clinicians and other health-care professionals with evidence-based recommendations on genetic and tumor testing for women diagnosed with epithelial ovarian cancer.1 “We wanted to go over the evidence and make strong statements and recommendations...
Ask Patients About Their Use of Dietary Supplements
A study finding that that patients who use antioxidant supplements, iron, and vitamin B12, before and during chemotherapy may be at increased risk of breast cancer recurrence and mortality confirms concerns about the use of these supplements. It also “absolutely reinforces the importance of asking...
Using Antioxidants and Other Supplements With Chemotherapy May Increase Risk of Breast Cancer Recurrence and Mortality
Using antioxidants and other dietary supplements before and during adjuvant chemotherapy for breast cancer may increase the risk of recurrence and “to a lesser extent, death,” according to an analysis of dietary and nutritional data from a phase III trial, published in the Journal of Clinical...
Drug Repository Programs Address High Costs, Access, and Waste Issues When Appropriately Implemented
On February 19, 2020, ASCO issued a news release about a position statement on state drug repository programs, outlining the Society’s support for drug repository programs solely for oral medications provided they are maintained within a closed system. The Society also makes recommendations to help ...
Hematologist Usama Gergis, MD, MBA, Joins Sidney Kimmel Cancer Center
The Sidney Kimmel Cancer Center–Jefferson Health (Sidney Kimmel) welcomes Usama Gergis, MD, MBA, as Director of the Bone Marrow Transplant and Immune Cellular Therapy Program and Professor in the Department of Medical Oncology, Division of Hematological Malignancies. Dr. Gergis joins Sidney Kimmel ...
Cancer Has Made Me the Person I Am, and I’m Grateful
The only clue that I was harboring a life-threatening cancer came as I was driving to a golf lesson in the fall of 2006, and I casually rubbed the left side of neck and felt a tiny bump. Although I wasn’t alarmed at the time, I did point out the mass to my primary care physician when I met with...
FDA Pipeline: Priority Reviews in Lung Cancers, Lymphoma
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to treatments for non–small cell and small cell lung cancers, as well as for diffuse large-B cell lymphoma (DLBCL); Breakthrough Therapy designation to an antibody-drug conjugate for bladder cancer; and a double Fast...
New Center for Indigenous Cancer Research at Roswell Park Has Regional Focus, Global Reach
Growing up on the Seneca Nation in Western New York, Rodney Haring, PhD, MSW, learned the concept of “The Good Mind,” largely from the matrilineal voices in his community. He calls this philosophy, which is one of the shaping principles of the Haudenosaunee people, “a strength from awareness of...
Searching for Evidence-Based Reassurance Where None Could Be Found
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
The Ohio State–James Cancer Repository Program Now Accepting Oral Cancer Therapy Donations for Patients in Need
Individuals are now able to donate no-longer-needed oral cancer therapy drugs to other persons with cancer through new state rules spearheaded by the State of Ohio Board of Pharmacy and The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove...
Quality of Life With Tisagenlecleucel Therapy for Relapsed or Refractory DLBCL
Adult patients with diffuse large B-cell lymphoma (DLBCL) whose disease was effectively treated with the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel showed sustained and clinically meaningful improvement in a variety of self-reported quality-of-life measures, according to...
Long-Term Outcomes With PD-1 Inhibitor Treatment and Response to Retreatment in Advanced Melanoma
In a single-center study reported in the Journal of Clinical Oncology, Allison Betof Warner, MD, PhD, and colleagues found that approximately three-quarters of patients with advanced melanoma achieving a complete response on programmed cell death protein 1 (PD-1) inhibitor therapy were alive...
Postmenopausal Estrogen and Risk of Breast Cancer: What Is the Real Story?
I am responding to an article in the January 25, 2020, issue of The ASCO Post on the conclusion of the 19-year follow-up on the Women’s Health Initiative (WHI) presented by Rowan T. Chlebowski, MD, PhD, at the 2019 San Antonio Breast Cancer Symposium: Postmenopausal estrogen administration does not ...
Using Machine Learning to Prompt Serious Illness Conversations
Despite research showing that among patients with cancer, early advance care planning conversations lead to care that is in alliance with patients’ goals and wishes, especially at the end of life,1 most patients die without having discussions about their treatment goals and end-of-life preferences ...
Expert Point of View: Chetasi Talati, MD
Chetasi Talati, MD, Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center, Tampa, Florida, commented on the study by Borthakur et al. “[Core-binding factor] acute myeloid leukemia (AML) represents a favorable-risk group of patients who are more chemosensitive and may...
FLAG-GO Achieves Deeper Remission Than FLAG-IDA in Favorable-Risk AML
Gemtuzumab ozogamicin, once approved in 2000 for the treatment of acute myeloid leukemia (AML), was taken off the market in 2010 due to toxicity concerns. Idarubicin has been used in place of gemtuzumab ozogamicin in some chemotherapy regimens. Gemtuzumab ozogamicin was reintroduced to the market...
Strong Activity Shown for Lisocabtagene Maraleucel CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma
Another CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be poised to enter the marketplace for aggressive relapsed or refractory large B-cell lymphoma, based on a high rate of rapid and durable complete responses achieved with lisocabtagene maraleucel. The phase I TRANSCEND NHL...
Edna Cukierman, PhD, Receives Grant to Study Biology of Pancreatic Cancer
Edna Cukierman, PhD, of Fox Chase Cancer Center, has received a $292,999 grant from Worldwide Cancer Research for a 2-year study of the microenvironment of pancreatic cancer cells. Dr. Cukierman, Associate Professor in the Cancer Biology Research Program and Co-Leader of the Marvin and Concetta...
Poster to Bedside: Geriatric Oncology Research Updates From 2019 ASCO Annual Meeting
Functional status impairment, limited mobility, comorbidities, polypharmacy, and other aging-related manifestations are common in older individuals. These conditions complicate the oncologic management of older adults, who are underrepresented in clinical trials, even though they form the majority ...
Pembrolizumab for BCG-Unresponsive, High-Risk Non–Muscle Invasive Bladder Cancer
On January 8, 2020, pembrolizumab was approved for treatment of patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.1,2...
BEACON-CRC: Quality of Life May Be Well Maintained With Targeted Treatment
For patients with previously treated metastatic colorectal cancer harboring BRAF V600E mutations, the phase III BEACON-CRC study showed the benefit for combining two or three targeted agents vs the standard of care.1 The study has now also shown a benefit for the triplet and doublet in maintaining ...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, and Multiple Myeloma
The ASH 2019 Annual Meeting & Exposition featured countless important sessions and lectures. It would be impossible to attend all the symposia, oral presentations, poster presentations, and special events. Below, we have selected some presentation highlights to supplement our coverage of the...
Bruton’s Tyrosine Kinase Inhibitor Yields High Overall Response Rates in del(17p) CLL and SLL
In findings of the SEQUOIA trial and updated results of the AU-003 trial,1,2 zanubrutinib, a Bruton’s tyrosine inhibitor (BTK), was shown to produce high overall response rates for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), even in the presence of...
Expert Point of View: Thierry Facon, MD, and Michael Jain, MD, PhD
Thierry Facon, MD, of Lille University Hospital in France, and Michael Jain, MD, PhD, of Moffitt Cancer Center, Tampa, were interviewed by The ASCO Post on the second-generation chimeric antigen receptor (CAR) T-cell products for treating multiple myeloma. According to Dr. Facon, essentially...
Next-Generation BCMA-Targeted CAR T-Cell Therapies for Relapsed or Refractory Multiple Myeloma Explored in Early-Phase Trials
Two novel dual-target chimeric antigen receptor (CAR) T-cell strategies are yielding early and durable responses for patients with relapsed or refractory multiple myeloma, as well as potentially less cytokine-release syndrome and neurotoxicity compared with first-generation CAR T-cell products,...
Combination Brentuximab Vedotin, Nivolumab Explored in First-Line, Salvage Therapies for Patients With Hodgkin Lymphoma
Two separate studies are investigating brentuximab vedotin plus nivolumab combination therapy for adults with Hodgkin lymphoma: one as first-line therapy and another as salvage therapy for relapsed/refractory classic disease, according to data presented at the 2019 Annual Meeting & Exposition...
Early Data Suggest Efficacy of Innovative CAR NK-Cell Therapy for B-Cell Malignancies
FT596, a novel off-the-shelf chimeric antigen receptor natural killer cell (CAR-NK) product, was as effective as existing CAR T-cell platforms in killing cancer cells in vivo, and the combination of FT596 plus rituximab killed lymphoma cancer cells that were no longer responding to CAR T-cell...
Bispecific Antibody Shows Activity in Post–CAR T-Cell Therapy for Non-Hodgkin Lymphoma
Mosunetuzumab, an investigational bispecific antibody, demonstrated activity in preliminary studies of patients with non-Hodgkin lymphoma (NHL), including those who are refractory to or relapsed after third-line chimeric antigen receptor (CAR) T-cell therapy. With further study, mosunetuzumab,...
Expert Point of View: Howard J. Weinstein, MD, and Robert A. Brodsky, MD
Commenting on the Children’s Oncology Group AALL1331 study, Howard J. Weinstein, MD, Chief of Pediatric HematologyOncology at Massachusetts General Hospital for Children and Harvard Medical School in Boston, said: “These are very promising results for children, adolescents, and young adults who...
Blinatumomab Post-reinduction Consolidation Improves Event-Free, Overall Survival vs Chemotherapy in Young Patients With B-Cell ALL
Among children, adolescents, and young adults with B-cell acute lymphoblastic leukemia (ALL), the bispecific T-cell engager blinatumomab improved event-free survival and overall survival, compared with standard chemotherapy, as post-reinduction consolidation therapy at first relapse prior to...
Expert Point of View: Basem M. William, MD, MRCP (UK), FACP, and Caron Jacobson, MD
Basem M. William, MD, MRCP (UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center, Columbus, said many of the new-generation bispecific antibodies are “highly promising.” He said they “are...
Will Bispecific Antibodies Compete With CAR T-Cell Therapy in Lymphoma?
Are second-generation bispecific antibodies the next big thing in lymphoma? Studies of these drugs were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. Years ago, the bispecific T-cell engager blinatumomab validated the concept of bispecific...
Conference Highlights From the 2019 American Society of Hematology Annual Meeting & Exposition
More than 25,000 specialists in hematology from over 115 countries attended the 61st American Society of Hematology (ASH) Annual Meeting & Exposition held last December in Orlando. The conference featured a stunning array of 4,900 abstracts with impressive new data in the treatment of multiple...
Ziad Bakouny, MD, on Metastatic Kidney Cancer: Defining the Role of Cytoreductive Nephrectomy
Ziad Bakouny, MD, of Dana-Farber Cancer Institute, discusses the controversial and ill-defined role of cytoreductive nephrectomy in treating patients with metastatic renal cell carcinoma who have received targeted therapies or immune checkpoint inhibitors (Abstract 608).
Julie N. Graff, MD, on Castration-Resistant Prostate Cancer: Results From KEYNOTE-199 on Pembrolizumab Plus Enzalutamide
Julie N. Graff, MD, of Oregon Health & Science University and Knight Cancer Institute, discusses study findings that show pembrolizumab plus enzalutamide after progression on enzalutamide produced clinical activity and can lead to durable responses, with a manageable safety profile. The phase...
Haploidentical Related Donor vs Unrelated Cord Blood Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphomas
In a retrospective analysis reported in the Journal of Clinical Oncology, Fatobene et al found that nonmyeloablative haploidentical related donor cell transplantation was associated with better outcomes compared to unrelated cord blood hematopoietic transplantation in patients with Hodgkin and...
Osimertinib Plus Savolitinib for EGFR-Mutated, MET-Amplified NSCLC After Disease Progression on EGFR Tyrosine Kinase Inhibitors
As reported in The Lancet Oncology, Lecia V. Sequist, MD, and colleagues have found activity and an acceptable risk-benefit profile with the combination of the third-generation EGFR tyrosine kinase inhibitor osimertinib and the MET tyrosine kinase inhibitor savolitinib in patients with EGFR...
ASCO/CCO Update Guideline for Selecting Systemic Treatment in Stage IV NSCLC Without Driver Mutations
ASCO and Cancer Care Ontario (CCO) have published an update to a joint guideline on systemic therapy for stage IV non–small cell lung cancer (NSCLC) without driver mutations.1 “The treatment of stage IV NSCLC has become increasingly more complicated, and, with the advent of immunotherapy and the...
Cervical Cancer Recurrence: Open vs Minimally Invasive Radical Hysterectomy
A multi-institutional retrospective study reported in the Journal of Clinical Oncology by Shitanshu Uppal, MBBS, and colleagues showed that minimally invasive radical hysterectomy was associated with a higher risk of disease recurrence vs open abdominal hysterectomy in women undergoing surgery for...
FDA Pipeline: Priority Reviews in Lymphoma, Lung Cancer, GIST, and Breast Cancer
This week, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents in lymphoma, lung cancer, gastrointestinal stromal tumors, and breast cancer, and granted Fast Track designation to a first-in-class radioenhancer hafnium oxide nanoparticle in head and neck cancer. Priority...
2020 GU Cancers Symposium: Talazoparib for Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer
According to results from a phase II trial presented by Johann S. de Bono, MD, PhD, and colleagues at the 2020 Genitourinary (GU) Cancers Symposium (Abstract 119), treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib showed antitumor activity in patients with metastatic...
2020 GU Cancers Symposium: Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
In patients with metastatic urothelial carcinoma, platinum chemotherapy is the standard of care in the first-line setting; however, for patients who are ineligible for platinum treatment, the alternative standard—gemcitabine plus carboplatin—can be poorly tolerated and have limited durability and...
Immune-Related Adverse Events in Patients With Cancer Receiving Influenza Vaccination During Treatment With Pembrolizumab
In a study reported in JCO Oncology Practice, Failing et al found that influenza vaccination did not increase the incidence of immune-related adverse events among patients receiving pembrolizumab for various cancers. On multivariate analysis, influenza vaccination was associated with a...
Ivana Sestak, PhD, on Clinical Treatment Score From TAILORx: Predicting Distant Breast Cancer Recurrence
Ivana Sestak, PhD, of Queen Mary University of London and the Centre for Cancer Prevention, discusses study findings that confirm the prognostic ability of the Clinical Treatment Score at 5 years (CTS5) for late distant recurrence, specifically for patients older than 50 years and/or for those...
Hongchao Pan, PhD, on an Update on 5 Years of Endocrine Therapy for Early Breast Cancer
Hongchao Pan, PhD, of the University of Oxford, discusses an analysis of 86,000 women in the Early Breast Cancer Trialists’ Collaborative Group database, which showed that the risk of distant recurrence 20 years after a diagnosis of node-negative, estrogen receptor–negative early-stage breast...
2020 GU Cancers Symposium: Fear of Recurrence, Patients’ Prognostic Understanding Examined in Genitourinary Cancers
In studies to be presented at the 2020 Genitourinary Cancers Symposium (Abstracts 649 and 665), researchers examined the prevalence of fear of cancer recurrence in patients with renal cell carcinoma and evaluated the prognostic understanding patients with genitourinary cancer possess of their...
Study Finds ‘Bridge’ to CAR T-Cell Therapy May Be Detrimental to Survival
The use of bridging therapy before treatment with axicabtagene ciloleucel was associated with worse overall survival in univariate, multivariate, and propensity score–matched analyses performed on data from the U.S. Lymphoma CAR T Consortium, investigators reported at the 2019 American Society of...
2020 GU Cancers Symposium: Oral HIF2A Inhibitor for Advanced Clear Cell Renal Cell Carcinoma
A novel, first-in-class, small molecule, hypoxia-inducible factor 2 alpha (HIF2A) inhibitor showed single-agent activity in heavily pretreated patients with metastatic clear cell renal cell carcinoma. These results from a phase I/II study will be presented by Toni Choueiri, MD, and colleagues at...
Therapy-Associated Polyposis in Survivors of Childhood Cancer
A report published by Biller et al in Cancer Prevention Research provides new details about a recently discovered condition in which childhood cancer survivors develop numerous colorectal polyps, despite not having a hereditary susceptibility to the condition. The condition—known as...
Plasma Circulating Tumor HPV DNA for the Detection of Recurrent HPV-Associated Oropharyngeal Cancer
In a study reported in the Journal of Clinical Oncology, Bhishamjit S. Chera, MD, and colleagues found that surveillance for circulating tumor human papillomavirus (HPV) DNA was accurate in identifying disease recurrence in patients with curatively treated HPV-associated oropharyngeal squamous cell ...
